Eli Lilly and Co
Obesity is a chronic disease. It’s why treating it will be so profitable unless payers push back
While there has been plenty of buzz about how successful patients have been in losing weight while taking a new class of obesity medications, there is a growing realization that when people stop taking these pricey drugs, the pounds can creep back on. There was a frank discussion of this on Eli Lilly’s first-quarter earnings […]
Read More
Being overweight drug marketplace could be really worth $200 billion in the decade, states Barclays, as sector valuations grow
The burgeoning pounds-decline drug market, which is whetting investors’ appetites with its pledge of combatting worldwide being overweight rates, could be value as a great deal as $200 billion inside of the following decade, in accordance to Barclays lender. Dubbing being overweight “the story of this ten years,” Barclays’ head of European pharmaceuticals fairness investigation […]
Read More
Eli Lilly says obesity drug tirzepatide resulted in weight loss of up to 34 pounds
A pharmacist displays a box of Mounjaro, a tirzepatide injection drug used for treating type 2 diabetes and made by Lilly at Rock Canyon Pharmacy in Provo, Utah, May 29, 2023. George Frey | Reuters Patients who took Eli Lilly‘s weight loss drug tirzepatide lost up to 34 pounds on average, or 16% of their […]
Read More
Stocks making the biggest moves premarket: Meta, Teladoc, Harley-Davidson, Southwest Airlines and more
Harley-Davidson motorcycles are displayed for sale at the Cowboy Harley-Davidson dealership on February 02, 2023 in Austin, Texas. Brandon Bell | Getty Images Check out the companies making headlines before the bell: Meta Platforms – Shares jumped 12% after the Facebook parent surpassed Wall Street’s expectations on the top and bottom lines and issued optimistic […]
Read More
Eli Lilly misses on earnings but raises full-year guidance
Medical bottles and syringe are seen with Eli Lilly and Company logo displayed on a screen in the background in this illustration photo taken in Krakow, Poland on November 10, 2022. Jakub Porzycki | Nurphoto | Getty Images Eli Lilly‘s first-quarter earnings missed expectations Thursday, but the pharmaceutical company raised its full-year guidance. Before the […]
Read More
Biogen isn’t concerned about competing with Eli Lilly in the Alzheimer’s drug space, CEO says
A person skateboards past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Adam Glanzman | Bloomberg | Getty Images Biogen isn’t worried about competing with Eli Lilly as they both attempt to bring an Alzheimer’s drug to the market, Biogen’s CEO said Tuesday. “I think it will be good if there are […]
Read More
Eli Lilly, Novo Nordisk and Sanofi CEOs to testify before Senate on lowering insulin prices
In this photo illustration, an insulin pen manufactured by the Novo Nordisk company is displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images News | Getty Images The top executives of the three drug companies that control 90% of the global insulin market will testify May 10 before the Senate Health […]
Read More
Senate legislation would cap insulin at $35 per month for people with private insurance
In this photo illustration, insulin pens manufactured by the Novo Nordisk company are displayed on March 14, 2023 in Miami, Florida. Joe Raedle | Getty Images Bipartisan Senate legislation introduced Friday would cap the price of insulin at $35 per month for people with private insurance. The bill, drafted by Sens. Jeanne Shaheen, D-N.H., and […]
Read More
Treasury yields minimal adjusted as concentration remains on economic outlook, earnings
John Zich | Bloomberg | Getty Visuals U.S. Treasury yields have been little changed on Tuesday, as traders continued to assess the outlook for the U.S. financial system and digested the most current spherical of company earnings. As of all around 5:25 a.m. ET, the yield on the benchmark 10-yr Treasury observe was fractionally higher […]
Read More
Credit score Suisse upgrades Novo Nordisk on ‘surprise’ advancement of weight problems and diabetic issues prescription drugs Ozempic and Wegovy
Credit history Suisse upgraded Danish pharmaceutical firm Novo Nordisk to outperform from neutral on Thursday, citing expansion in its weight problems and diabetes medications. Body weight-reduction drug Wegovy has experienced a profitable relaunch soon after working with supply issues, when diabetes drug Ozempic has witnessed accelerating advancement as a substitute of moderation following Wegovy’s relaunch, […]
Read More